Antonia Sambola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonia Sambola has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Abdallah Almaghraby
Department of Cardiology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication- Arwa Mehmood Wahid
Department of Cardiology, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Passeig de la Vall d’Hebron 119–129, 08035 Barcelona, Spain
1 shared publication - Badiha Herranz1 shared publication
- Barbara Izquierdo Coronel
Cardiology Department, Getafe University Hospital, Madrid, Spain
1 shared publication - Bernard Iung
Hôpital Bichat, Paris, France
1 shared publication - Borja Ibanez
Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain
1 shared publication
Latest Publications
European Infective Endocarditis (EURO-ENDO) score for predicting 30-day mortality in left-sided infective endocarditis
Background: A major challenge in managing left-sided infective endocarditis (LSIE) is identifying patients who will benefit from surgery including those with prohibitive operative risk. However, no widely validated models are currently available to estimate 30-day mortality early after the initial diagnostic evaluation in the broader LSIE population including patients managed without surgery. We aimed to develop and externally validate the European Infective Endocarditis (EURO-ENDO) risk score for predicting 30-day mortality in patients with LSIE. Methods: The prospective, multicentre European Society of Cardiology (ESC)-EURObservational Research Programme EURO-ENDO registry included 2171 patients with LSIE diagnosed according to ESC 2015 criteria. Clinical, biological, microbiological and imaging variables were analysed and a multivariable logistic regression model was developed. Internal validation was performed using bootstrap resampling. External validation was conducted in an independent temporal cohort of 377 consecutive patients with LSIE from two tertiary centres in Barcelona, Spain, recruited between 2019 and 2024. Results: Among 2140 registry patients included in the final analysis, 254 (11.9%) died within 30 days. Eleven variables were independently associated with 30-day mortality and included in the EURO-ENDO prediction model: previous stroke or transient ischaemic attack, previous cardiac surgery, heart failure or cardiogenic shock, creatinine >2 mg/dL, vegetations >10 mm, severe regurgitation, abscess, negative blood cultures, Staphylococcus aureus infection, absence of surgical indication and surgical indication without intention to operate. The model showed good discrimination and calibration (area under the receiver operating characteristic (AUROC) 0.763; Hosmer-Lemeshow p=0.825; Brier score 0.09). In the external validation cohort, 48/377 patients (12.7%) died; discrimination remained excellent (AUROC 0.799; 95% CI 0.730 to 0.868) with good calibration (slope 1.017; expected-to-observed ratio 1.124). Conclusions: The EURO-ENDO risk score, incorporating 11 variables available during the initial diagnostic evaluation, accurately predicts individualised 30-day mortality in patients with LSIE and showed consistent performance in both internal and external validation cohorts. This tool may support early risk stratification, multidisciplinary endocarditis team discussions and clinical decision-making ( https://scoreei.web.app/score ).
European Infective Endocarditis (EURO-ENDO) score for predicting 30-day mortality in left-sided infective endocarditis
Background: A major challenge in managing left-sided infective endocarditis (LSIE) is identifying patients who will benefit from surgery including those with prohibitive operative risk. However, no widely validated models are currently available to estimate 30-day mortality early after the initial diagnostic evaluation in the broader LSIE population including patients managed without surgery. We aimed to develop and externally validate the European Infective Endocarditis (EURO-ENDO) risk score for predicting 30-day mortality in patients with LSIE. Methods: The prospective, multicentre European Society of Cardiology (ESC)-EURObservational Research Programme EURO-ENDO registry included 2171 patients with LSIE diagnosed according to ESC 2015 criteria. Clinical, biological, microbiological and imaging variables were analysed and a multivariable logistic regression model was developed. Internal validation was performed using bootstrap resampling. External validation was conducted in an independent temporal cohort of 377 consecutive patients with LSIE from two tertiary centres in Barcelona, Spain, recruited between 2019 and 2024. Results: Among 2140 registry patients included in the final analysis, 254 (11.9%) died within 30 days. Eleven variables were independently associated with 30-day mortality and included in the EURO-ENDO prediction model: previous stroke or transient ischaemic attack, previous cardiac surgery, heart failure or cardiogenic shock, creatinine >2 mg/dL, vegetations >10 mm, severe regurgitation, abscess, negative blood cultures, Staphylococcus aureus infection, absence of surgical indication and surgical indication without intention to operate. The model showed good discrimination and calibration (area under the receiver operating characteristic (AUROC) 0.763; Hosmer-Lemeshow p=0.825; Brier score 0.09). In the external validation cohort, 48/377 patients (12.7%) died; discrimination remained excellent (AUROC 0.799; 95% CI 0.730 to 0.868) with good calibration (slope 1.017; expected-to-observed ratio 1.124). Conclusions: The EURO-ENDO risk score, incorporating 11 variables available during the initial diagnostic evaluation, accurately predicts individualised 30-day mortality in patients with LSIE and showed consistent performance in both internal and external validation cohorts. This tool may support early risk stratification, multidisciplinary endocarditis team discussions and clinical decision-making ( https://scoreei.web.app/score ).
- Open Access
- 3 September 2026
- Published by AccScience Publishing in Health Psychology Research
- p. 026280153
Early evolution of psychological functioning after Takotsubo syndrome: A prospective cohort study
Background: Although ventricular function usually recovers rapidly after Takotsubo syndrome (TTS), little is known about the early evolution of psychological functioning. Objectives: In this study, we examined longitudinal changes across multiple psychological domains during the first month in patients with TTS, patients with acute myocardial infarction (AMI), and healthy controls (HC). Methods: Eighty-five participants (37 TTS, 23 AMI, and 25 HC) completed psychological assessments during the acute phase and 30 days later. The assessment included symptoms of anxiety and depression, anger, coping strategies, emotion regulation, resilience and worry. Longitudinal changes were evaluated using linear mixed-effects models including fixed effects for group, time, and the group × time interaction, with a random intercept for participants. Results: A significant group × time interaction was observed for anger-in control, with patients with AMI showing a greater increase over time than HC; this interaction remained significant after false discovery rate (FDR) correction for multiple testing. An interaction was also observed for cognitive coping in the primary analysis, but it did not remain significant after FDR correction and was therefore considered exploratory. Conclusion: Most psychological outcomes did not show statistically significant longitudinal changes during the first month after TTS. These findings highlight the importance of incorporating psychological assessment into routine follow-up after TTS.
- 3 September 2026
- Published by AccScience Publishing in Health Psychology Research
- p. 026280153
Open AccessEarly evolution of psychological functioning after Takotsubo syndrome: A prospective cohort study
Background: Although ventricular function usually recovers rapidly after Takotsubo syndrome (TTS), little is known about the early evolution of psychological functioning. Objectives: In this study, we examined longitudinal changes across multiple psychological domains during the first month in patients with TTS, patients with acute myocardial infarction (AMI), and healthy controls (HC). Methods: Eighty-five participants (37 TTS, 23 AMI, and 25 HC) completed psychological assessments during the acute phase and 30 days later. The assessment included symptoms of anxiety and depression, anger, coping strategies, emotion regulation, resilience and worry. Longitudinal changes were evaluated using linear mixed-effects models including fixed effects for group, time, and the group × time interaction, with a random intercept for participants. Results: A significant group × time interaction was observed for anger-in control, with patients with AMI showing a greater increase over time than HC; this interaction remained significant after false discovery rate (FDR) correction for multiple testing. An interaction was also observed for cognitive coping in the primary analysis, but it did not remain significant after FDR correction and was therefore considered exploratory. Conclusion: Most psychological outcomes did not show statistically significant longitudinal changes during the first month after TTS. These findings highlight the importance of incorporating psychological assessment into routine follow-up after TTS.
- Open Access
- 28 April 2023
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 81 (4) , 338-349
Cardiovascular disease in women: Do we need new diagnostic and therapeutic strategies?
Cardiovascular disease (CVD) is the leading cause of death worldwide affecting both sexes equally. However, in comparison to men, in women, it often is underrecognized and undertreated in both primary and secondary prevention settings. It is clear, that in the healthy population, there are profound differences both anatomically and biochemically between women and men, and this may impact how both groups present when they become ill. Moreover, some diseases affect more frequently women than men such as myocardial ischemia or infarction without obstructive coronary disease, Takotsubo syndrome, some atrial arrhythmias, or heart failure with preserved ejection fraction. Therefore, diagnostic and therapeutic strategies that have been established largely on the basis of clinical studies with a predominantly male population must be adapted before being applied to women. There is a paucity of data regarding cardiovascular disease in women. It is inadequate to only perform a subgroup analysis evaluating a specific treatment or invasive technique when women constitute fifty percent of the population. In this regard, this may affect the time of clinical diagnosis and severity assessments of some valvulopathies. In this review, we will focus on the differences in the diagnosis, management, and outcomes for women with the most frequent cardiovascular pathologies including coronary artery disease, arrhythmia, heart failure, and valvopathies. In addition, we will describe diseases that exclusively affect women that are related to pregnancy, and some of them are life-threatening. Although the lack of research on women plays a role in the poorer outcomes in women, especially in ischemic heart disease, some techniques such as transcatheter aortic valve implantation and transcatheter edge-to-edge therapy seem to have better outcomes in women.
- 28 April 2023
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 81 (4) , 338-349
Open AccessCardiovascular disease in women: Do we need new diagnostic and therapeutic strategies?
Cardiovascular disease (CVD) is the leading cause of death worldwide affecting both sexes equally. However, in comparison to men, in women, it often is underrecognized and undertreated in both primary and secondary prevention settings. It is clear, that in the healthy population, there are profound differences both anatomically and biochemically between women and men, and this may impact how both groups present when they become ill. Moreover, some diseases affect more frequently women than men such as myocardial ischemia or infarction without obstructive coronary disease, Takotsubo syndrome, some atrial arrhythmias, or heart failure with preserved ejection fraction. Therefore, diagnostic and therapeutic strategies that have been established largely on the basis of clinical studies with a predominantly male population must be adapted before being applied to women. There is a paucity of data regarding cardiovascular disease in women. It is inadequate to only perform a subgroup analysis evaluating a specific treatment or invasive technique when women constitute fifty percent of the population. In this regard, this may affect the time of clinical diagnosis and severity assessments of some valvulopathies. In this review, we will focus on the differences in the diagnosis, management, and outcomes for women with the most frequent cardiovascular pathologies including coronary artery disease, arrhythmia, heart failure, and valvopathies. In addition, we will describe diseases that exclusively affect women that are related to pregnancy, and some of them are life-threatening. Although the lack of research on women plays a role in the poorer outcomes in women, especially in ischemic heart disease, some techniques such as transcatheter aortic valve implantation and transcatheter edge-to-edge therapy seem to have better outcomes in women.